{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:42:02Z","timestamp":1792226522148,"version":"4.4.0"},"reference-count":9,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100020021","name":"Avant Foundation","doi-asserted-by":"publisher","award":["MMG000222025"],"award-info":[{"award-number":["MMG000222025"]}],"id":[{"id":"10.13039\/501100020021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Rituximab is endorsed internationally as first\u2010line therapy for moderate\u2010to\u2010severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single\u2010centre retrospective cohort, 24 adults with pemphigus vulgaris (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200916) or pemphigus foliaceus (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20098) received rituximab as part of routine care; median follow\u2010up from first infusion was 24.9\u2009months. Disease control was documented in all patients and complete remission in 20 (83%), of whom half subsequently relapsed despite most receiving more than one cycle. Adverse events occurred in eight patients (33%), predominantly mild infusion\u2010related reactions, with one fatal pneumonia. These real\u2010world data support planned maintenance after remission rather than single\u2010course rescue use, and prospective multicentre study with standardised severity scoring.\n                  <\/jats:p>","DOI":"10.1111\/ajd.70221","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:19:13Z","timestamp":1792225153000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1372-7345","authenticated-orcid":false,"given":"Pokphazz","family":"Christjaroon","sequence":"first","affiliation":[{"name":"Department of Dermatology Sydney Children's Hospital  Randwick New South Wales Australia"},{"name":"Faculty of Medicine and Health University of New South Wales  Sydney New South Wales Australia"},{"name":"Department of Dermatology Liverpool Hospital  Liverpool New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5165-7537","authenticated-orcid":false,"given":"Ali","family":"Abid","sequence":"additional","affiliation":[{"name":"Department of Dermatology Liverpool Hospital  Liverpool New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4466-6985","authenticated-orcid":false,"given":"Orli","family":"Wargon","sequence":"additional","affiliation":[{"name":"Department of Dermatology Sydney Children's Hospital  Randwick New South Wales Australia"},{"name":"Faculty of Medicine and Health University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6484-0355","authenticated-orcid":false,"given":"Paul","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Dermatology Liverpool Hospital  Liverpool New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-9757","authenticated-orcid":false,"given":"Artiene","family":"Tatian","sequence":"additional","affiliation":[{"name":"Department of Dermatology Sydney Children's Hospital  Randwick New South Wales Australia"},{"name":"Faculty of Medicine and Health University of New South Wales  Sydney New South Wales Australia"},{"name":"Department of Dermatology Liverpool Hospital  Liverpool New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"e_1_2_1_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.26"},{"key":"e_1_2_1_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.021"},{"key":"e_1_2_1_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13804"},{"key":"e_1_2_1_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012"},{"key":"e_1_2_1_10_6_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"National Cancer Institute","year":"2017"},{"key":"e_1_2_1_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18482"},{"key":"e_1_2_1_10_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005166"},{"key":"e_1_2_1_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.042"},{"key":"e_1_2_1_10_10_1","volume-title":"Biosimilar Medicine Fact Sheet\u2014Rituximab","author":"Australian Government Department of Health and Aged Care","year":"2022"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.70221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:19:14Z","timestamp":1792225154000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.70221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":9,"alternative-id":["10.1111\/ajd.70221"],"URL":"https:\/\/doi.org\/10.1111\/ajd.70221","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"2026-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajd.70221"}}